X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc (XFOR): 11 pipeline candidates · 4 upcoming catalysts · ~34 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
34.4 months
D/E 0.60 · 34% dilution
Lead: Approved
11 candidates
4 upcoming, next in ~195d
0 buys · 1 sell (180d)
A transparent, data-derived signal for X4 Pharmaceuticals, Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$379.6M
Cash
$217.5M
Quarterly Burn
$19.6M
Runway
34.4 mo
Revenue
$2.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| 2mg cs0159 | Phase 3 |
| arcalyst | Approved |
| dapagliflozin | Approved |
| enzalutamide | Approved |
| ixazomib | Phase 3 |
| jab-23e73 | Phase 1/Phase 2 |
| nintedanib | Approved |
| nintedanib | Approved |
| nv-5138 | Phase 2 |
| x4p-003 | Preclinical |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
78
Total value held
$311.8M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 13,475,296 | $55.7M |
| morgan stanley | 9,466,992 | $39.1M |
| fmr llc | 8,103,400 | $33.5M |
| vanguard capital management llc | 6,995,224 | $28.9M |
| deep track capital, lp | 6,339,535 | $26.2M |
| braidwell lp | 3,272,954 | $13.5M |
| rosalind advisors, inc. | 3,214,766 | $13.3M |
| blackstone inc. | 2,681,922 | $11.1M |
| trails edge capital partners, lp | 2,571,478 | $10.6M |
| nantahala capital management, llc | 2,449,468 | $10.1M |
Showing top 10 of 78 institutional holders of X4 Pharmaceuticals, Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in X4 Pharmaceuticals, Inc's pipeline?
X4 Pharmaceuticals, Inc (XFOR) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is X4 Pharmaceuticals, Inc's lead drug candidate?
X4 Pharmaceuticals, Inc's most advanced tracked candidate is 2mg cs0159 (Phase 3) for Primary Biliary Cholangitis (PBC); Primary Biliary Cholangitis.
What is X4 Pharmaceuticals, Inc's next catalyst?
X4 Pharmaceuticals, Inc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positiv" — expected December 30, 2026.
What is X4 Pharmaceuticals, Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, X4 Pharmaceuticals, Inc has approximately 34.4 months of cash runway.
What is X4 Pharmaceuticals, Inc's market capitalization?
X4 Pharmaceuticals, Inc's market capitalization is approximately $379.6M.
Get the full picture on X4 Pharmaceuticals, Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.